Your browser doesn't support javascript.
loading
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
Chesney, Jason A; Puzanov, Igor; Collichio, Frances A; Singh, Parminder; Milhem, Mohammed M; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore; Hauschild, Axel; Lebbé, Celeste; Joshi, Harshada; Snyder, Wendy; Mehnert, Janice M.
Afiliación
  • Chesney JA; J. Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA jason.chesney@louisville.edu.
  • Puzanov I; Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Collichio FA; The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Singh P; Mayo Clinic, Phoenix, Arizona, USA.
  • Milhem MM; University of Iowa Hospitals and Clinics, Iowa City, lowa, USA.
  • Glaspy J; University of California Los Angeles School of Medicine, Los Angeles, California, USA.
  • Hamid O; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, USA.
  • Ross M; MD Anderson Cancer Center, Houston, Texas, USA.
  • Friedlander P; Mount Sinai School of Medicine, New York, New York, USA.
  • Garbe C; University Hospital Tuebingen, Tuebingen, Germany.
  • Logan T; Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA.
  • Hauschild A; Department of Dermatology, University of Kiel, Kiel, Germany.
  • Lebbé C; Université de Paris AP-HP Dermatology CIC Departments, Hôpital Saint-Louis, Paris, France.
  • Joshi H; Parexel, Hyderabad, India.
  • Snyder W; Amgen Inc, Thousand Oaks, California, USA.
  • Mehnert JM; Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.
J Immunother Cancer ; 11(5)2023 05.
Article en En | MEDLINE | ID: mdl-37142291
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Herpesvirus Humano 1 / Virus Oncolíticos / Viroterapia Oncolítica / Melanoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Herpesvirus Humano 1 / Virus Oncolíticos / Viroterapia Oncolítica / Melanoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos